---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121103"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:23:54.008259+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada

## Summary
- Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.
- CASGEVY approved for SCD and TDT in Switzerland and Canada; 45 ATCs activated globally.
- Approximately 40 patients have had cell collections across all regions as of mid-October.
- CTX112 Phase 1 data to be presented at ASH 2024: 67% ORR, 44% CRR in lymphoma patients.
- R&D expenses $82.2M (down from $90.7M); collaboration expense net $11.2M (down from $23.4M).

## SEC filing metadata
- accession: 0000950170-24-121103
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017024121103/0000950170-24-121103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017024121103/crsp-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121103
- JSON: https://secwatch.observer/filing/0000950170-24-121103.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.